Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of antithrombin alfa (ATryn) in hereditary antithrombin deficiency during high-risk thrombosis situations
2005-002014-38Phase 3Completed
- Sponsor
- rEVO Biologics
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of antithrombin III in congenital antithrombin deficiency (ATD) and venous thromboembolism (VTE), sponsored by rEVO Biologics. Primary endpoints: Incidence of acute deep venous thrombosis (DVT) and Incidence of other thromboembolic events. Started Sep 2005; status: completed.
02
Drugs
antithrombin III
03
Conditions
congenital antithrombin deficiency (ATD)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2005-002014-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002014-38.